Search: onr:"swepub:oai:gup.ub.gu.se/294928" >
Persistence with ID...
Persistence with IDegLira in Patients in Clinical Practice: A Nationwide Observational Study in Sweden
-
- Eliasson, Björn, 1959 (author)
- Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för molekylär och klinisk medicin,Institute of Medicine, Department of Molecular and Clinical Medicine
-
Ekelund, J. (author)
-
Miftaraj, M. (author)
-
show more...
-
Ranthe, M. F. (author)
-
- Mårdby, Ann-Charlotte, 1976 (author)
- Gothenburg University,Göteborgs universitet,Institutionen för medicin,Institute of Medicine
-
Fernandes, J. D. D. (author)
-
- Svensson, Ann-Marie, 1961 (author)
- Gothenburg University,Göteborgs universitet,Institutionen för medicin,Institute of Medicine
-
show less...
-
(creator_code:org_t)
- 2020-07-03
- 2020
- English.
-
In: Diabetes Therapy. - : Springer Science and Business Media LLC. - 1869-6953 .- 1869-6961. ; 11, s. 1807-1820
- Related links:
-
https://link.springe...
-
show more...
-
https://gup.ub.gu.se...
-
https://doi.org/10.1...
-
show less...
Abstract
Subject headings
Close
- Aims To explore persistence with insulin degludec/liraglutide (IDegLira) treatment, clinical characteristics and concomitant medications in a large population of patients in clinical practice. Methods This was an observational study in patients with type 2 diabetes (n = 2432) who initiated IDegLira between 26 May 2015 and 31 December 2017. Data were obtained from Swedish nationwide registers and linked on an individual level using unique Swedish personal identifiers. Dose calculations were made for patients with >= 180 days between the first and last collections of IDegLira prescription. Changes in clinical parameters were evaluated as change from the last observation during 12 months prior to the initiation date until +/- 90 days from the last collection of IDegLira. Results Pre-index regimens (index date being the date of filling the first prescription of IDegLira) included: multiple daily insulin injections (45.1%); insulin and glucagon-like peptide-1 receptor agonist (GLP-1 RA) (19.7%); long-acting insulins (11.8%); non-injectable therapy only (11.4%); GLP-1 RA only (9.8%); and no collection of diabetes medication during the 6-month pre-index period (2.3%). The majority of patients (94 and 84%) were persistent with IDegLira at 6 and 12 months, respectively. The most commonly used concomitant medication was metformin (69.4%). Mean daily dose was 33 dose steps. Overall, there was a mean decrease in HbA1c (approx. 10 mmol/mol [1%]) and body weight (- 1.1 kg). Improvements in HbA1c were observed regardless of pre-index treatment. Conclusion After 12 months, 84% of patients were persistent on IDegLira, with improved glycaemic control and reductions in body weight.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Endokrinologi och diabetes (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Endocrinology and Diabetes (hsv//eng)
Keyword
- GLP-1 analogue
- Insulin therapy
- Liraglutide
- Real-world
- Type 2
- diabetes
- fixed-ratio combination
- insulin degludec/liraglutide ideglira
- glycemic
- control
- cardiovascular outcomes
- naive patients
- basal insulin
- type-2
- liraglutide
- efficacy
- degludec
- Endocrinology & Metabolism
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database